DMTK vs. XGN, PMD, CNTG, BGLC, RNLX, ENZ, PSNL, RNXT, HLTH, and FLGC
Should you be buying DermTech stock or one of its competitors? The main competitors of DermTech include Exagen (XGN), Psychemedics (PMD), Centogene (CNTG), BioNexus Gene Lab (BGLC), Renalytix (RNLX), Enzo Biochem (ENZ), Personalis (PSNL), RenovoRx (RNXT), Cue Health (HLTH), and Flora Growth (FLGC).
DermTech (NASDAQ:DMTK) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.
In the previous week, Exagen's average media sentiment score of 1.36 beat DermTech's score of 0.00 indicating that Exagen is being referred to more favorably in the news media.
20.5% of DermTech shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 5.1% of DermTech shares are held by insiders. Comparatively, 36.8% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Exagen has higher revenue and earnings than DermTech. Exagen is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
Exagen has a net margin of -45.08% compared to DermTech's net margin of -659.57%. Exagen's return on equity of -80.28% beat DermTech's return on equity.
DermTech has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
DermTech presently has a consensus price target of $2.38, suggesting a potential upside of 266.04%. Exagen has a consensus price target of $6.00, suggesting a potential upside of 341.18%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than DermTech.
DermTech received 27 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 57.50% of users gave DermTech an outperform vote while only 52.78% of users gave Exagen an outperform vote.
Summary
Exagen beats DermTech on 12 of the 17 factors compared between the two stocks.
Get DermTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DermTech Competitors List
Related Companies and Tools
